177 related articles for article (PubMed ID: 27193130)
1. Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience.
Kempf E; Desamericq G; Vieites B; Diaz-Padilla I; Calvo E; Estevez P; Garcia-Arreza A; Martinez-Maestre MA; Duran I
Clin Transl Oncol; 2017 Feb; 19(2):173-179. PubMed ID: 27193130
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the anatolian society of medical oncology.
Bilici A; Inanc M; Ulas A; Akman T; Seker M; Babacan NA; Inal A; Bal O; Koral L; Sevinc A; Tufan G; Elkiran ET; Ustaalioglu BB; Yavuzsen T; Alkis N; Ozkan M; Gumus M
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6493-9. PubMed ID: 24377556
[TBL] [Abstract][Full Text] [Related]
3. Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients.
Ray-Coquard I; Weber B; Lotz JP; Tournigand C; Provencal J; Mayeur D; Treilleux I; Paraiso D; Duvillard P; Pujade-Lauraine E;
Gynecol Oncol; 2010 Oct; 119(1):53-9. PubMed ID: 20580063
[TBL] [Abstract][Full Text] [Related]
4. Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes.
Tangjitgamol S; Hanprasertpong J; Manusirivithaya S; Wootipoom V; Thavaramara T; Buhachat R
Acta Obstet Gynecol Scand; 2010; 89(2):182-9. PubMed ID: 19961281
[TBL] [Abstract][Full Text] [Related]
5. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
6. [Clinical analysis of 15 cases of malignant ovarian germ cell tumors with lung metastasis].
Liu Y; Ren T; Feng FZ; Wan XR; Shen K; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):40-4. PubMed ID: 22455692
[TBL] [Abstract][Full Text] [Related]
7. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
8. Outcome and prognostic factors in ovarian germ cell malignancies.
Lai CH; Chang TC; Hsueh S; Wu TI; Chao A; Chou HH; Wang PN
Gynecol Oncol; 2005 Mar; 96(3):784-91. PubMed ID: 15721426
[TBL] [Abstract][Full Text] [Related]
9. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
Blanchard P; Plantade A; Pagès C; Afchain P; Louvet C; Tournigand C; de Gramont A
Gynecol Oncol; 2007 Jan; 104(1):41-5. PubMed ID: 16952391
[TBL] [Abstract][Full Text] [Related]
10. Outcome of recurrent and persistent disease of malignant ovarian germ cell tumor: a retrospective analysis at King Chulalongkorn Memorial Hospital.
Lertkhachonsuk R; Manchana T; Termrungruanglert W; Vasuratna A; Sittisomwong T; Worasethsin P; Sirisabya N; Khemapech N; Tresukosol D
J Med Assoc Thai; 2006 Feb; 89(2):138-44. PubMed ID: 16578998
[TBL] [Abstract][Full Text] [Related]
11. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
[TBL] [Abstract][Full Text] [Related]
12. Malignant ovarian germ cell tumors: a single-institution experience.
Cicin I; Eralp Y; Saip P; Ayan I; Kebudi R; Iyibozkurt C; Tuzlali S; Gorgun O; Topuz E
Am J Clin Oncol; 2009 Apr; 32(2):191-6. PubMed ID: 19307952
[TBL] [Abstract][Full Text] [Related]
13. Clinical management of malignant ovarian germ cell tumors: A 26-year experience in a tertiary care institution.
Hu T; Fang Y; Sun Q; Zhao H; Ma D; Zhu T; Wang C
Surg Oncol; 2019 Dec; 31():8-13. PubMed ID: 31446304
[TBL] [Abstract][Full Text] [Related]
14. The Factors Predicting Recurrence in Patients With Serous Borderline Ovarian Tumor.
Ureyen I; Karalok A; Tasci T; Turkmen O; Boran N; Tulunay G; Turan T
Int J Gynecol Cancer; 2016 Jan; 26(1):66-72. PubMed ID: 26512785
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience.
Faure-Conter C; Orbach D; Cropet C; Baranzelli MC; Martelli H; Thebaud E; Vérité C; Rome A; Fasola S; Corradini N; Rocourt N; Frappaz D; Kalfa N; Patte C
Pediatr Blood Cancer; 2014 Feb; 61(2):253-9. PubMed ID: 23940114
[TBL] [Abstract][Full Text] [Related]
16. Development of a risk stratification system to guide treatment for female germ cell tumors.
Meisel JL; Woo KM; Sudarsan N; Eng J; Patil S; Jacobsen EP; Murali R; Gardner GJ; Bosl GJ; Aghajanian C; Feldman DR
Gynecol Oncol; 2015 Sep; 138(3):566-72. PubMed ID: 26115974
[TBL] [Abstract][Full Text] [Related]
17. [Malignant ovarian germ cell tumors--clinical characteristics and analysis of outcomes].
Miedzińska-Maciejewska M; Bobkiewicz P; Gawrychowski K
Ginekol Pol; 2011 May; 82(5):338-43. PubMed ID: 21851031
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of lymphadenectomyin malignant ovarian sex cord stromal tumor: A retrospective cohort study and meta-analysis.
Cheng H; Peng J; Yang Z; Zhang G
Gynecol Oncol; 2018 Jan; 148(1):91-96. PubMed ID: 29107349
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
20. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
